The Bone Cancer Research Trust has published its latest Research Impact Report, marking a significant milestone in its 10-year strategy to improve outcomes for bone cancer patients.
The report outlines the charity's progress up to March 2025 and celebrates the collective achievements of researchers, patients and supporters since its previous edition in 2023.
With a steadfast commitment to collaborative and life-changing research, the charity has now invested over £11 million in research since 2006 — including £3.2 million committed in the last two years alone.
This makes the charity almost 60% of the way to its strategic goal of investing £10 million as outlined in its 10-year strategy More Patients Surviving. More Patients Thriving.
At the heart of this progress is the charity's emphasis on patient-led insight. Its Patient and Public Involvement Panel (PPIP) has played a pivotal role in shaping how research impact is defined and communicated, ensuring the voices of patients and families are central to the research process.
Key achievements in the report include:
- AD-ICONIC completed its first year, gathering crucial information to improve survival and quality of life for people living with osteosarcoma
- Introduction of Lenvatinib to the rEECur clinical trial, expanding treatment options for Ewing sarcoma patients
- 95 research grants funded over the past two years, 67 of which support early career researchers — fostering new ideas, fresh perspectives, and building the next generation of leaders in the field
- Infrastructure Grants have facilitated the collection of over 14,000 patient samples since they began in 2017. The more samples available, the better researchers can understand tumour subtypes and tailor treatments
Dr Zoe Davison, Director of Research and Information at the Bone Cancer Research Trust, shared:
This report showcases the huge progress made possible by our supporters and the wider bone cancer community. Every research project, every trial, every new sample collected brings us closer to better treatments and brighter futures for patients. We have made huge strides, but we're not done yet. The continued dedication of our community is vital as we continue working towards each patient having the best chance of survival and quality of life.
Read the full report and summary: